Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.

Yip WK, Bonetti M, Cole BF, Barcella W, Wang XV, Lazar A, Gelber RD.

Clin Trials. 2016 Aug;13(4):382-90. doi: 10.1177/1740774516643297. Epub 2016 Apr 19.

PMID:
27094489
2.

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD.

J Clin Oncol. 2016 Jul 1;34(19):2221-31. doi: 10.1200/JCO.2015.64.3171. Epub 2016 Apr 4.

PMID:
27044936
3.

Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.

Huang XZ, Gao P, Song YX, Sun JX, Chen XW, Zhao JH, Ma B, Wang J, Wang ZN.

Oncotarget. 2016 Apr 12;7(15):19643-53. doi: 10.18632/oncotarget.7544.

4.

Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.

An MW, Han Y, Meyers JP, Bogaerts J, Sargent DJ, Mandrekar SJ.

J Clin Oncol. 2015 Dec 1;33(34):4048-57. doi: 10.1200/JCO.2015.60.8778. Epub 2015 Oct 26.

PMID:
26503199
5.

Immune monitoring technology primer.

Dobbin KK.

J Immunother Cancer. 2015 Oct 20;3:40. doi: 10.1186/s40425-015-0086-9. eCollection 2015. Erratum in: J Immunother Cancer. 2015;3:56.

6.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group.

Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22.

PMID:
26493064
7.

Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Ondra T, Dmitrienko A, Friede T, Graf A, Miller F, Stallard N, Posch M.

J Biopharm Stat. 2016;26(1):99-119. doi: 10.1080/10543406.2015.1092034.

8.

The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment.

Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ.

J Natl Cancer Inst. 2015 Jun 24;107(8). pii: djv157. doi: 10.1093/jnci/djv157. Print 2015 Aug.

9.

Detecting treatment-covariate interactions using permutation methods.

Wang R, Schoenfeld DA, Hoeppner B, Evins AE.

Stat Med. 2015 May 30;34(12):2035-47. doi: 10.1002/sim.6457. Epub 2015 Mar 2.

10.

A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.

Tian L, Alizadeh AA, Gentles AJ, Tibshirani R.

J Am Stat Assoc. 2014 Oct;109(508):1517-1532.

11.

Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Baker SG, Kramer BS.

Clin Trials. 2015 Aug;12(4):299-308. doi: 10.1177/1740774514557725. Epub 2014 Nov 10.

12.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

13.

Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.

Claggett B, Tian L, Castagno D, Wei LJ.

Biostatistics. 2015 Jan;16(1):60-72. doi: 10.1093/biostatistics/kxu037. Epub 2014 Aug 12.

14.

Evaluating marker-guided treatment selection strategies.

Matsouaka RA, Li J, Cai T.

Biometrics. 2014 Sep;70(3):489-99. doi: 10.1111/biom.12179. Epub 2014 Apr 29.

15.

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P.

Cancer. 2014 Aug 1;120(15):2325-33. doi: 10.1002/cncr.28669. Epub 2014 Apr 15.

16.

An approach to evaluating and comparing biomarkers for patient treatment selection.

Janes H, Brown MD, Huang Y, Pepe MS.

Int J Biostat. 2014;10(1):99-121. doi: 10.1515/ijb-2012-0052.

17.

Protocolized Care for Early Septic Shock (ProCESS) statistical analysis plan.

Pike F, Yealy DM, Kellum JA, Huang DT, Barnato AE, Eaton TL, Angus DC, Weissfeld LA; ProCESS Investigators.

Crit Care Resusc. 2013 Dec;15(4):301-10.

18.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

19.

EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY.

Zhao L, Tian L, Cai T, Claggett B, Wei LJ.

J Am Stat Assoc. 2013 Jan 1;108(502):527-539.

20.

A framework for evaluating markers used to select patient treatment.

Janes H, Pepe MS, Huang Y.

Med Decis Making. 2014 Feb;34(2):159-67. doi: 10.1177/0272989X13493147. Epub 2013 Jun 27.

Items per page

Supplemental Content

Write to the Help Desk